Partner Content Partner Content In-vitro Diagnostics Market profiled Qiagen, Becton Dickinso... In-vitro Diagnostics Market will reach $95bn by 2025
News Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face